Trends in Real-World Neovascular AMD Treatment Outcomes in the UK

References

• Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–e349. doi:10.1016/S2214-109X(13)70113-X
   PubMed Web of Science ®Google Scholar
• Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900–1901. doi:10.1001/jama.291.15.1900
   PubMedGoogle Scholar
• Li JQW, Schmid M, Letow J, Wolpers AC, Holz FG, Finger RP. EURETINA. Retinal Diseases in Europe: Prevalence. Incidence and Healthcare Needs. Bonn, Germany; 2017. Available from: https://www.euretina.org/downloads/EURETINA_Retinal_Diseases.pdf. Accessed September 30, 2020.
   Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina. 2003;23(6):741–751. doi:10.1097/00006982-200312000-00001
   Web of Science ®Google Scholar
• Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752–756. doi:10.1136/bjophthalmol-2011-301109
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109(9):1232–1241. doi:10.1001/archopht.1991.01080090056026
   Google Scholar
• Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121(5):667–673. doi:10.1001/archopht.121.5.667
   Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331–335. doi:10.3928/1542-8877-20050701-14
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383–390.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363–372.e365. doi:10.1016/j.ophtha.2005.11.019
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912–918. doi:10.1001/archopht.1982.01030030920003
   PubMedGoogle Scholar
• Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database Syst Rev. 2019;4(3):CD005139.
   Google Scholar
• Rahman F, Zekite A, Bunce C, Jayaram H, Flanagan D. Recent trends in vision impairment certifications in England and Wales. Eye (Lond). 2020;34(7):1271–1278. doi:10.1038/s41433-020-0864-6
   Web of Science ®Google Scholar
• Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–146. doi:10.1016/j.preteyeres.2017.12.002
   PubMed Web of Science ®Google Scholar
• Lee AY, Lee CS, Butt T, et al. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol. 2015;99(8):1045–1050. doi:10.1136/bjophthalmol-2014-306229
   Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418–1431. doi:10.1097/IAE.0000000000001142
   PubMed Web of Science ®Google Scholar
• Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol. 2016;69:199–207.e2. doi:10.1016/j.jclinepi.2015.07.010
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual. Manchester, UK; 2014. Available from: https://www.nice.org.uk/process/pmg20/. Accessed September 30, 2020.
   Google Scholar
• Almuhtaseb H, Kanavati S, Rufai SR, Lotery AJ. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye (Lond). 2017;31(6):878–883. doi:10.1038/eye.2017.6
   Web of Science ®Google Scholar
• Basheer K, Mensah E, Khanam T, Minakaran N. Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. Clin Ophthalmol. 2015;9:959–965. doi:10.2147/OPTH.S76754
   Google Scholar
• Borooah S, Jeganathan VS, Ambrecht AM, et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond). 2015;29(9):1156–1161. doi:10.1038/eye.2015.83
   Web of Science ®Google Scholar
• Buckle M, Donachie PH, Johnston RL. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. Br J Ophthalmol. 2016;100(2):240–245. doi:10.1136/bjophthalmol-2014-306423
   Web of Science ®Google Scholar
• Chavan R, Panneerselvam S, Adhana P, Narendran N, Yang Y. Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. Clin Ophthalmol. 2014;8:717–723. doi:10.2147/OPTH.S60763
   Google Scholar
• Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2017;174:160–168. doi:10.1016/j.ajo.2016.09.038
   PubMed Web of Science ®Google Scholar
• Fasler K, Moraes G, Wagner S, et al. One- and two-year visual outcomes from the moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource. BMJ Open. 2019;9(6):e027441. doi:10.1136/bmjopen-2018-027441
   Web of Science ®Google Scholar
• Fulcher C, Hazel CA, Pacey I, Ali H, Ghanchi FD. Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: data from a real-world clinical setting. Eur J Ophthalmol. 2020;30(3):543–549.
   Web of Science ®Google Scholar
• Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol. 2011;95(3):386–390. doi:10.1136/bjo.2010.179499
   Web of Science ®Google Scholar
• Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol. 2011;95(4):530–533. doi:10.1136/bjo.2009.171868
   Web of Science ®Google Scholar
• Lee AY, Lee CS, Egan CA, et al. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017;101(12):1683–1688. doi:10.1136/bjophthalmol-2016-309818
   Web of Science ®Google Scholar
• Muniraju R, Ramu J, Sivaprasad S. Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmologica. 2013;230(1):27–33. doi:10.1159/000350238
   Web of Science ®Google Scholar
• Ozturk M, Harris ML, Nguyen V, Barthelmes D, Gillies MC, Mehta H. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol. 2018;46(4):407–411. doi:10.1111/ceo.13085
   PubMed Web of Science ®Google Scholar
• Razi F, Haq A, Tonne P, Logendran M. Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin Ophthalmol. 2016;10:313–319. doi:10.2147/OPTH.S97775
   Google Scholar
• Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exp Ophthalmol. 2011;39(1):5–8.
   Web of Science ®Google Scholar
• Talks JS, Lotery AJ, Ghanchi F, et al. First-year visual acuity outcomes of providing aflibercept according to the VIEW Study Protocol for age-related macular degeneration. Ophthalmology. 2016;123(2):337–343. doi:10.1016/j.ophtha.2015.09.039
   Web of Science ®Google Scholar
• Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ. 2010;340:c2459. doi:10.1136/bmj.c2459
   PubMed Web of Science ®Google Scholar
• Vardarinos A, Gupta N, Janjua R, Iron A, Empeslidis T, Tsaousis KT. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. BMC Ophthalmol. 2017;17(1):58. doi:10.1186/s12886-017-0451-1
   Web of Science ®Google Scholar
• Williams GS, Seow E, Evans H, Owoniyi M, Evans S, Blyth C. Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration. Saudi J Ophthalmol. 2015;29(3):187–191. doi:10.1016/j.sjopt.2015.02.004
   Google Scholar
• Yang Y, Downey L, Mehta H, et al. Resource use and real-world outcomes for ranibizumab treat and extend for neovascular age-related macular degeneration in the UK: interim results from TERRA. Ophthalmol Ther. 2017;6(1):175–186. doi:10.1007/s40123-017-0091-9
   PubMed Web of Science ®Google Scholar
• Chandra S, Rasheed R, Menon D, et al. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration. Eye (Lond). 2020:1–9.
   Web of Science ®Google Scholar
• Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B. Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8). Clin Ophthalmol. 2019;13:2461–2467. doi:10.2147/OPTH.S218378
   Web of Science ®Google Scholar
• Almuhtaseb H, Johnston RL, Talks JS, Lotery AJ. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye (Lond). 2017;31(11):1582–1588. doi:10.1038/eye.2017.108
   Web of Science ®Google Scholar
• Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;96(12):1469–1473. doi:10.1136/bjophthalmol-2012-302167
   Web of Science ®Google Scholar
• Ross AH, Donachie PH, Sallam A, et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond). 2013;27(1):56–64. doi:10.1038/eye.2012.225
   PubMed Web of Science ®Google Scholar
• Tufail A, Xing W, Johnston R, et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092–1101.
   Web of Science ®Google Scholar
• Tan SZ, Laude A, Aspinall PA, Ambrecht AM, Vani A, Dhillon B. Decisional answer tree analysis of exudative age-related macular degeneration treatment outcomes. Int Ophthalmol. 2013;33(5):467–474. doi:10.1007/s10792-013-9717-7
   Web of Science ®Google Scholar
• Rodrigues IA, Sprinkhuizen SM, Barthelmes D, et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. Am J Ophthalmol. 2016;168:1–12. doi:10.1016/j.ajo.2016.04.012
   Web of Science ®Google Scholar
• Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117(11):2134–2140. doi:10.1016/j.ophtha.2010.02.032
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Tufail A, Margaron P, Guerin T, Larsen M. Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. Br J Ophthalmol. 2020;104(5):672–677. doi:10.1136/bjophthalmol-2018-313682
   Web of Science ®Google Scholar
• Ho AC, Saroj N, Baker K, et al. Impact of baseline characteristics on treatment response to intravitreal aflibercept injection for wet age-related macular degeneration. Ophthalmol Retina. 2018;2(7):676–683. doi:10.1016/j.oret.2017.10.017
   Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. doi:10.1016/j.ophtha.2013.08.011
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
   PubMed Web of Science ®Google Scholar
• Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122(9):1837–1845. doi:10.1016/j.ophtha.2015.05.010
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175–1183. doi:10.1016/j.ophtha.2011.12.016
   PubMed Web of Science ®Google Scholar
• Sadda SR, Guymer R, Mones JM, Tufail A, Jaffe GJ. Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion. Ophthalmology. 2020;127(5):648–659. doi:10.1016/j.ophtha.2019.11.010
   PubMed Web of Science ®Google Scholar
• Mones J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243(1):1–8. doi:10.1159/000502747
   Web of Science ®Google Scholar
• Liew G, Lee AY, Zarranz-Ventura J, et al. The UK neovascular AMD database report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (Lond). 2016;30(11):1462–1468. doi:10.1038/eye.2016.149
   Web of Science ®Google Scholar
• Nguyen V, Daien V, Guymer RH, et al. Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. Clin Exp Ophthalmol. 2018;46(3):266–274.
   Web of Science ®Google Scholar
• Denniston AK, Lee AY, Lee CS, et al. United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services. Br J Ophthalmol. 2019;103(6):837–843. doi:10.1136/bjophthalmol-2018-312568
   PubMed Web of Science ®Google Scholar
• Amoaku W, Balaskas K, Cudrnak T, et al. Initiation and maintenance of a treat-and-extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. Clin Ophthalmol. 2018;12:1731–1740. doi:10.2147/OPTH.S174560
   PubMed Web of Science ®Google Scholar
• Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond). 2019;33(Suppl 1):1–21.
   Web of Science ®Google Scholar
• Weber M, Dominguez M, Coscas F, et al. Impact of intravitreal aflibercept dosing regimens in treatment-naive patients with neovascular age-related macular degeneration: 2-year results of RAINBOW. BMC Ophthalmol. 2020;20(1):206. doi:10.1186/s12886-020-01468-z
   Web of Science ®Google Scholar
• Patel PJ, Devonport H, Sivaprasad S, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957–1966. doi:10.2147/OPTH.S145732
   Web of Science ®Google Scholar
• Ross AH, Downey L, Devonport H, et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond). 2020;34(10):1825–1834. doi:10.1038/s41433-019-0747-x
   PubMed Web of Science ®Google Scholar
• Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143–149. doi:10.3928/23258160-20140306-08
   PubMed Web of Science ®Google Scholar
• Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66–74. doi:10.1016/j.ophtha.2017.07.005
   PubMed Web of Science ®Google Scholar
• Ng WY, Tan GS, Ong PG, et al. Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2015;159(3):557–564.e551. doi:10.1016/j.ajo.2014.12.005
   Web of Science ®Google Scholar
• Gillies MC, Walton R, Liong J, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina. 2014;34(1):188–195. doi:10.1097/IAE.0b013e318296b271
   PubMed Web of Science ®Google Scholar
• Keenan TD, Kelly SP, Sallam A, Mohamed Q, Tufail A, Johnston RL. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol. 2013;97(9):1168–1172. doi:10.1136/bjophthalmol-2013-303233
   PubMed Web of Science ®Google Scholar
• Hassell JB, Weih LM, Keeffe JE. A measure of handicap for low vision rehabilitation: the impact of vision impairment profile. Clin Exp Ophthalmol. 2000;28(3):156–161. doi:10.1046/j.1442-9071.2000.00312.x
   PubMed Web of Science ®Google Scholar
• Thomas DS, Warwick A, Olvera-Barrios A, et al. Estimating excess visual loss in people with neovascular age-related macular degeneration during the COVID-19 pandemic. medRxiv. 2020.
   Google Scholar
• Amoaku W, Bailey C, Downey L, et al. Providing a safe and effective intravitreal treatment service: strategies for service delivery. Clin Ophthalmol. 2020;14:1315–1328. doi:10.2147/OPTH.S233061
   PubMed Web of Science ®Google Scholar
• Royal College of Ophthalmologists. The Way Forward. Options to Help Meet Demand for the Current and Future Care of Patients with Eye Disease —age-Related Macular Degeneration and Diabetic Retinopathy. London, UK; 2017. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2015/10/RCOphth-The-Way-Forward-AMD-300117.pdf . Accessed September 30, 2020.
   Google Scholar